How do you pay?

How to pay the least

Ask for the cash price

Lonsurf

We didn’t find one.

  1. Ask your pharmacy for Lonsurf’s cash price, and one or two other pharmacies too.
  2. Lonsurf’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameLonsurf
Authorized generictrifluridine and tipiracil
Regular generictrifluridine and tipiracil
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Lonsurf?
The original
–
–

Brand nameThe maker’s card

Taiho Oncology Patient Support (LONSURF Co-pay Program)

Savings card from Taiho Pharmaceutical (Taiho Oncology)

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 per treatment cycle

Sign up on lonsurf.com 

In the maker’s words

“Eligible patients may pay $0 per treatment cycle…”

From the maker’s offer on lonsurf.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Lonsurf itself, from the same company, sold without the brand name, and usually for less. For now Lonsurf is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with:

  • metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Source: the FDA label for Lonsurf (Taiho Pharmaceutical Co., Ltd.), November 5, 2025. Full label on DailyMed 

Good to know